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Abstract 
 The signaling pathways that regulate the synthesis and structure of proteoglycans 
secreted by vascular smooth muscle cells are potential therapeutic targets for preventing 
lipid deposition in the early stage of atherosclerosis. PDGF stimulates both core protein 
expression and elongation of glycosaminoglycan (GAG) chains on proteoglycans. In this 
study we investigated the effects of the tyrosine kinase inhibitor genistein on PDGF 
mediated receptor phosphorylation and proteoglycan synthesis in human vascular smooth 
muscle cells. We demonstrate that genistein does not block phosphorylation of the 
activation site of the PDGF receptor at Tyr
857
 and two other downstream sites Tyr
751
 and 
Tyr
1021
. Genistein blocked PDGF-mediated proteoglycan core protein synthesis however 
it had no effect on GAG chain elongation. These results differ markedly to two other 
tyrosine kinase inhibitors, imatinib and Ki11502, that block PDGF receptor 
phosphorylation and PDGF mediated GAG elongation. We conclude that the action of 
genistein on core protein synthesis does not involve the PDGF receptor and that PDGF 
mediates GAG elongation via the PDGF receptor.
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Introduction 
The underlying pathology of most cardiovascular disease (CVD) is atherosclerosis 
[1, 2]. Atherosclerosis is characterized by a preinflammatory stage involving the 
deposition and retention of atherogenic lipoproteins by modified proteoglycans in the 
vessel wall followed by the later chronic non-resolving inflammatory stage involving the 
accumulation of immunogenic products and the formation of atherosclerotic plaques [3-
5]. A recent human pathology study showed unequivocally that the deposition of 
extracellular low density lipoproteins (LDL) in association with the proteoglycan 
biglycan, precedes the inflammatory response [6, 7]. LDL binds to proteoglycans and 
specifically the chondroitin sulfate/dermatan sulfate (CS/DS) glycosaminoglycan (GAG) 
chains in an interaction known as the “response to retention” hypothesis which has 
recently been reviewed by Boren and colleagues [3, 8]. Vasoactive and proatherogenic 
growth factors and hormones stimulate vascular smooth muscle cells (VSMC) resulting 
in an increase in the size of the GAG chains on secreted proteoglycans [9-12]. Longer 
GAG chains are associated with increased binding in vitro to LDL [9, 13, 14].  
Genistein is a pharmacological and nutraceutical of broad interest because it is 
present in the diet at potentially efficacious levels [15]. First reports of the tyrosine kinase 
inhibitory activity of genistein came in 1987 when Akiyama found that tyrosine 
phosphorylation of the epidermal growth factor  (EGF) receptor was decreased in the 
presence of genistein [16]. Recognised as a broad spectrum tyrosine kinase inhibitor, 
genistein exerts an inhibitory action by competitively inhibiting the binding of ATP in the 
kinase reaction [17]. The mechanism of action of genistein is probably the basis for its 
wide range of tyrosine kinase inhibition as the ATP binding domain is highly conserved 
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[17]. As well as inhibition of the EGF receptor, genistein has also been reported as 
inhibiting the PDGF receptor (PDGFR) [18] and the Insulin-like Growth Factor 
(IGF) receptor [19].   
Platelet-derived growth factor (PDGF) stimulates core protein expression for the 
CS/DS proteoglycan, versican, and also mediates elongation of GAG chains on all CS/DS 
proteoglycans secreted by VSMCs including, versican, biglycan and decorin [10, 20]. 
Genistein is a broad spectrum ATP competitive tyrosine kinase inhibitor known to inhibit 
the effects of PDGF on VSMCs [16, 18, 21, 22]. Genistein inhibits VSMC proliferation 
although it is almost two orders of magnitude less potent than compounds like imatinib 
and Ki11502 [21, 23]. 
An early finding in this area of signaling and proteoglycan synthesis was that 
PDGF-stimulated versican expression (in monkey VSMCs) was blocked by genistein, 
used as a tyrosine kinase inhibitor, but in the same experiments and therefore under 
identical conditions, the GAG elongation response to PDGF was not blocked by genistein 
[18]. This result lead to the interpretation that the signaling for core protein expression 
and GAG elongation were distinct processes and notably that the GAG elongation 
response mediated by PDGF was independent of the tyrosine kinase activity of the PDGF 
receptor [24].  
We recently reported that two PDGF receptor inhibitors, Ki11502 [25] and imatinib 
[13] block PDGF receptor mediated core protein expression, in this case for biglycan, and 
also block GAG elongation in human VSMCs [13, 25]. This data strongly suggests that 
the GAG elongation effect of PDGF is mediated by PDGF receptor phosphorylation [26]. 
Thus, the question is unresolved as to why the protein tyrosine kinase inhibitor genistein 
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which blocks PDGF stimulated proliferation and even blocks the PDGF expression of 
versican in VSMCs does not block PDGF stimulated GAG elongation [18]. This is a 
potentially very important pathway because imatinib treatment of human VSMCs leads to 
reduced binding of proteoglycans to LDL and reduced the deposition of lipid in the vessel 
wall of high fat fed ApoE
-/-
 mice [13]. In view of the potential therapeutic implications 
for this area [3, 4, 27, 28] we have further investigated the signaling pathway through 
which PDGF mediates its effects on proteoglycan synthesis in human VSMCs and 
specifically investigated the role of the PDGF receptor and its autophosphorylation 
including an investigation of the effects of genistein on PDGF receptor phosphorylation 
and downstream signaling of proteoglycan synthesis. 
We demonstrate that in intact VSMCs, genistein does not block PDGF receptor 
phosphorylation at Tyr
857
 which is the autophosphorylation and activation site nor does it 
block two other phosphorylation sites on the receptor. In contrast, two known PDGF 
receptor antagonists block PDGF receptor phosphorylation at all three target sites. PDGF 
stimulated versican expression is blocked by the three agents, and PDGF stimulated GAG 
elongation is blocked by the PDGF antagonists but not by genistein. These data 
demonstrate the specificity of the signaling pathways for proteoglycan core protein 
expression and GAG elongation providing an opportunity for the identification and 
development of specific antagonists of proteoglycan synthesis for potential use in 
diseases involving proteoglycans. 
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2 Materials and Methods. 
2.1 Materials 
Genistein, daidzein, benzamidine hydrochloride, DEAE-Sephacel, Sepharose CL-
6B, proteinase K, chondroitin sulfate, PDGF, thrombin and penicillin-streptomycin were 
from Sigma Chem Co. (St Louis, MO, USA). Imatinib was from Alfred Hospital 
Pharmacy. and PDGFRβ inhibitor Ki11502 from Calbiochem. Corp. Dulbecco’s 
Modified Eagle Medium (DMEM) was from Invitrogen Corporation, USA.  Foetal 
bovine serum (FBS) and penicillin-streptomycin-fungizone solution, PDGF BB, 
Sepharose CL-6B and other standard reagents were purchased from Sigma-Aldrich 
Australia. Sulfur-35 Na2SO4 ([
35
S]-sulfate) and Trans
35
STrans[
35
S]-label ([
35
S]-Met/Cys) 
were from MP Biomedicals, USA. Cetyl pyridinium chloride (CPC) was from Unilab 
Chemicals and Pharmaceuticals, Mumbai, India.  
 
2.2 Cell Culture 
Human VSMCs from internal mammary arteries and the saphenous veins were 
isolated and characterised as previously described [29] from patients undergoing 
coronary artery bypass grafting at Alfred Health (Melbourne, Australia.). The acquisition 
of the vessel segments was approved by the Alfred Hospital Human Ethics committee. 
HSMCs and WKY12-22 SMCs for Egr-1 experiments were cultured in Waymouth’s 
medium (Life Technologies, Inc.), pH 7.4, supplemented with 10 units/ml penicillin, 
10ug/ml streptomycin, and 10% fetal calf serum at 37˚C and 5% CO2 in an air jacketed 
CO2 incubator. SMCs were growth-arrested in serum-free medium for 24 h prior to 
inhibitors addition. HSMCs were incubated with genistein 100 μM, imatinib 1 μM, 
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daidzein 100 μM, Ki11502 (300 nM) and PDGFRβ inhibitor 10μM for 1 h.  Cells were 
then stimulated with 50 ng/ml PDGF-BB for 30 min before mRNA and protein isolation.  
 
2.3 Quantitation of radiolabel incorporation into proteoglycans 
Quiescent human VSMCs in 24 well plates were treated in 0.5ml 5mM glucose 
DMEM, 0.1% FBS, 0.1% DMSO inhibitors as detailed in Results section and exposed to 
[
35
S]-SO4 (50Ci/ml) in the presence of PDGF (50ng/ml) for 24 h.  Secreted 
proteoglycans were harvested and [
35
S]-SO4 incorporation into proteoglycans was 
quantitated using the CPC precipitation assay [9, 30-32]. 
 
2.4 SDS-PAGE determination of proteoglycan size 
Proteoglycans labelled with [
35
S]sulfate or [
35
S]-Met/Cys were prepared for SDS-
PAGE by isolation through DEAE sephacel anionic exchange mini columns. Samples 
were added to pre-equilibrated columns, then washed extensively with low salt buffer 
(8M Urea, 0.25M NaCl, 2 mM disodium EDTA, 0.5% Triton X-100). Proteoglycans 
were eluted with high salt buffer (8M Urea, 3M NaCl, 2mM disodium EDTA, 0.5% 
Triton X-100) Aliquots (25,000 cpm) were precipitated (1.3% potassium acetate, 95% 
ethanol) and chondroitin sulfate was added as a cold carrier. Samples were resuspended 
in buffer (8M Urea, 2mM disodium EDTA, pH 7.5), to which an equal volume of sample 
buffer was added. Radiolabelled proteoglycans were separated on 4-13% acrylamide gels 
with a 3% stacking gel at 50V overnight. [
14
C]-protein molecular weight markers were 
run simultaneously. Processed and dried gels were exposed to a phosphorimaging screen 
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(Fuji Photo Film Co, Japan) for approximately 3 days, and then scanned on a Bio-
imaging analyser BAS-1000 MacBas (Fuji Photo Film Co, Japan). 
 
2.5 PDGFβ receptor direct kinase assays 
To investigate the inhibitory activities of several compounds against members of 
the PDGF receptor tyrosine kinase the Alphascreen™ P-Tyr-100 (phosphotyrosine) assay 
kit was used.  This assay is a bead based luminescent proximity assay in which the 
binding of molecules captured on donor and acceptor beads leads to an energy transfer.  
In a 384 well microplate, phosphotyrosine assay buffer (10mM HEPES, 25mM NaCl, 
10mM MgCl2, 0.01% Tween-20, 0.05mM sodium orthovanadate, 0.3% DMSO, 10L) 
containing the compound under investigation (0-100M) was mixed with the kinase 
(10L) at a predetermined optimal concentration.  The plate was sealed and incubated at 
room temperature for 20 min followed by the addition of 1M Kinase Substrate Biotin 
(Biotin Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Trp-Gly-Trp-Met-Asp-Phe-
NH2 in 5mg/ml BSA in PBS) containing ATP (80-625M) in phosphotyrosine assay 
buffer (10L).  The plate was resealed and incubated for 1 h at 30oC.  Anti-
phosphotyrosine acceptor beads and streptavidin donor beads were centrifuged 
(1000 rpm, 1 min) and diluted 1:100 in buffer (10mM HEPES, 25mM NaCl, 0.1M 
EDTA, 0.01% Tween-20, 0.1% BSA, pH 7.2).  Donor and acceptor beads (10L) were 
added to each well under low lighting conditions, the plate sealed and protected from 
light for 1h at room temperature.  The plate seal was removed and after a two minute 
delay, read on a microplate reader (Fusion™- microplate analyser, Perkin Elmer) at 
520-620nm. 
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2.6 Reverse transcription PCR for versican mRNA 
RNA from cultured VSMC cells was extracted with use of TriZol (Invitrogen, 
Carlsbad, CA, USA) following the manufacturer's protocol and reverse transcription was 
performed using All-in-one First-strand cDNA synthesis kit (GeneCopoeia, USA). The 
PCR program (32 cycles) consisted of denaturation for 5min at 94°C, and 94°C for 30 
seconds, annealing at 55°C for 30 seconds, then extension at 72°C for 1min, and 
extension at 72°C for 5 min. NCDN primer sequences were: forward; 5'- 
GCCGCCTTCCAAGGCCAAGA -3'; reverse; 5'- GCCCCTCACCGGTGGGCTTT -3'. 
The PCR products were examined on 1.2%  agarose gels with ethidium bromide staining. 
 
2.7 Determination of Egr-1  
Total RNA Preparation and Reverse Transcripatase Reaction – Cells were washed 
twice with cold PBS and total RNA was extracted with TRIzol® (Life Technologies, 
Inc.).  cDNA was synthesized from 5 μg of RNA using the Super Script III First Strand 
Synthesis Kit (Invitrogen, Carlsbad, USA) as per manufacturer’s instructions. cDNA was 
then stored at -20ºC. 
Real-time PCR – Real-time quantitative PCR was performed using ABI 
PRISM7700 Sequence Detection System in a final volume of 20 µl containing 1 µl of 
cDNA, 12.5 µl of SYBR Green Master Mix (Applied Biosystems), 0.5 µM of forward 
and reverse primers (Sigma) in DNAse free water at the following PCR conditions: 50°C 
for 20 min, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.   The 
target primers for amplifying Human Egr-1 were forward primer: 5’-AGC AGC ACC 
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TTC AAC CCT CA-3’ and reverse primer: 5’-CAG CAC CTT CTC GTT GTT CAG A-
3’. Human Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the 
internal control with sequence for forward primer: 5’-GAA GGC TGG GGC TCA TTT-
3’ and for reverse primer: 5’-CAG GAG GCA TTG CTG ATG AT-3’ . All experiments 
for real-time RT-PCR were performed in triplicate and data was analysed using the 
comparative Ct method. Results are shown as fold induction of mRNA. Primer product 
size was verified on a 2% agarose/TBE gel.  
 
2.8 Western blots  
Total cell lysates were resolved on 10% SDS-PAGE and transferred onto PVDF. 
Membranes were blocked with 5% skim milk powder, incubated with antibodies as 
described previously [25]. Phospho-PDGF receptor-β (Tyr857), phospho-PDGF receptor β 
(Tyr
1021
) Egr-1 and β-actin antibodies were from Santa Cruz Biotechnology Inc. USA, 
phospho- PDGF receptor-β (Tyr751) antibodies were purchased from Cell Signaling 
Technology USA. Anti-human smooth muscle actin antibody was from DakoCytomation 
Denmark. Secondary antibodies were HRP-anti-species specific IgG and were followed 
by ECL detection (Amersham). 
 
2.9 Statistical analyses 
Data was analysed for statistical significance using a 1-way analysis of variance 
(ANOVA). Results were considered statistically significant at P <0.05 or P <0.01 as 
stated. Normalisation of data was performed in some investigations to adjust for control 
variations between individual experiments with data shown as mean  SEM. 
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3 Results 
It has previously been reported that genistein inhibits PDGF stimulated [
35
S]-sulfate 
incorporation into proteoglycans secreted by primate VSMCs but it does not block the 
GAG elongation action of PDGF [18, 24]. To assess if these results pertain to human 
VSMCs and to extend these findings in relation to the involvement of the PDGF receptor 
we investigated the effects of genistein and its less active structural analogue, daidzein, 
along with a well characterised inhibitor, imatinib on PDGF-stimulated proteoglycan 
synthesis in human VSMCs [13]. Daidzein is the 5-dehydroxy derivative of genistein and 
lacks tyrosine kinase inhibitory activity [33]. PDGF treatment of VSMCs resulted in an 
almost one and a half fold increase in [
35
S]-sulfate incorporation into total secreted 
proteoglycans over 24 h (Fig. 1, upper panel). Each of the antagonists had a small 
inhibitory effect on basal rate of incorporation of [
35
S]-sulfate most likely due to some 
basal level of secretion and activation by growth factors [34]. Radiosulfate incorporation 
in PDGF treated cells was completely blocked to the basal plus drug level by imatinib 
(1 µM) and genistein (100 µM) and it was not blocked by the inactive kinase inhibitor 
analogue, daidzein (100 μM) (Fig. 1 upper panel). We then examined the effect of the 
pharmacological inhibitors on the average apparent size of the biglycan molecules 
secreted by the human VSMCs (Fig. 1, lower panel). For these molecules the apparent 
size determined by SDS-PAGE correlates well with size exclusion chromatography [13, 
25, 28]. PDGF treatment caused an increase in the average size of biglycan molecules 
and this response was completely blocked by imatinib and unaffected by genistein and 
daidzein (Fig. 1, lower panel). These data confirm the original seminal findings of 
Schonherr and colleagues [18]. 
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We then examined the effects of the pharmacological agents on PDGF stimulated 
proteoglycan core protein expression and secretion. The CPC precipitation method used 
to assess the culture media after metabolic labelling with [
35
S]-met/cys specifically 
isolates and allows the quantitation of total proteoglycan core proteins [35, 36]. Although 
the monkey cells used by Schonherr et al. predominantly secreted versican, the human 
VSMCs used in this study secrete predominantly biglycan [18, 25]. PDGF stimulated a 
small increase in [
35
S]-met/cys incorporation into secreted proteoglycans and this was 
blocked by imatinib and genistein and less so by daidzein (Fig. 2, upper panel). We then 
examined the effect of PDGF on versican mRNA levels in these cells (Fig 2, lower panel). 
PDGF treatment lead to an increase in versican mRNA in these human cells as previously 
reported in monkey VSMCs [18, 37]. The increase in versican mRNA due to treatment of 
cells with PDGF was inhibited by genistein (Fig. 2, lower panel). This data is consistent 
with and confirms the data of Schonherr et al. [18] that genistein blocks PDGF stimulated 
core protein expression and specifically the expression of versican but it does not block 
GAG elongation stimulated by PDGF [18]. 
PDGF signaling occurs through the initial phosphorylation of the 
autophosphorylation site (Tyr
857
) (human PDGFβ receptor isotype) in the cytosolic split 
kinase domain of the receptor followed by the internal autophosphorylation of multiple 
tyrosine residues throughout the cytosolic domain [26, 38]. We analysed the 
pharmacology of three of these sites associated with the human PDGFRβ signaling 
related to the synthesis of proteoglycans [25] – the autophosphorylation site Tyr857, Tyr751 
which is associated with Phosphatidyl Inositol-3-Kinase signaling and Tyr
1021
 associated 
with Phospholipase-γ signaling. Assessing the phosphorylation by Western blotting with 
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site specific antibodies showed that the 3 index sites were rapidly and strongly 
phosphorylated following treatment of cells with PDGF (data not shown). For all three of 
the target sites the phosphorylation was blocked by imatinib and Ki11502 but it was 
completely unaffected by genistein at the same concentration (100 µM) which completely 
inhibited PDGF stimulated [
35
S]-sulfate incorporation and core protein expression in the 
experiments shown in Figs. 1 and 2 (Fig. 3). We investigated whether genistein blocked 
tyrosine phosphorylation of proteins other than the PDGF receptor using an anti-
phosphotyrosine antibody on whole cell lysates (Figure 3). The data shows that genistein 
had a negligible effect on the basal phosphotyrosine proteins of vascular smooth muscle 
cells. At least ten discrete tyrosine phosphorylated proteins were induced or increased 
after PDGF treatment. Genistein partially or completely blocked at least four of these 
PDGF-mediated tyrosine phosphorylated proteins and they were not blocked by imatinib. 
This clearly shows that genistein can inhibit tyrosine phosphorylation of proteins other 
than the PDGF receptor.  
We then investigated the possibility that there might be signaling independent of 
the receptor phosphorylation for which there is a small amount of evidence [39, 40]. For 
example, it has been demonstrated that the PDGF mediated induction of Egr-1 is 
independent of the PDGF receptor autophosphorylation on tyrosine [40] so we 
investigated this possibility in the current model. PDGF stimulated a large increase in the 
expression of mRNA [3] (Fig. 4, upper panel) and protein (Fig. 4, lower panel) for Egr-1. 
PDGF stimulation of Egr-1 expression was partially inhibited by the PDGF receptor 
antagonist, imatinib (Fig. 4, upper and lower panels). The inhibitory response to genistein 
and daidzein was consistent with their relative activity at tyrosine kinase receptors in that 
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genistein was inhibitory and daidzein had no effect (Fig. 4). The data indicates that 
genistein inhibits a process, most likely a phosphorylation step that leads to Egr-1 
expression but this is not occurring at the PDGF receptor.  
To further explore the interaction of genistein and the other PDGF receptor 
antagonists with the PDGF receptor kinase activity, we assessed the effect of multiple 
agents of interest on PDGF receptor kinase activity in a cell-free in vitro system using the 
Alphascreen™ P-Tyr-100 (phosphotyrosine) assay kit. The inhibitory potency of the 
agents was in the order Ki11502>imatinib>genistein>>daidzein (Fig. 5 and data analysis 
in Table 1) which is consistent with experimental evidence in several cells systems [13, 
21, 41]. Notably, genistein was a full albeit low potency inhibitor of PDGF receptor 
kinase activity (Fig. 5, upper panel). The calculated parameters relating to the fit of this 
data to logistical equations is shown in Table 1. This data raises the question as to why 
genistein did not inhibit the PDGF stimulated phosphorylation of Tyr
857
 (and other sites) 
in intact cells as shown in Fig. 3. Kinase inhibitors are mostly of the type that they act by 
blocking the interaction of the ATP binding site on the kinase with ATP [16, 42]. For 
practical reasons of sensitivity in vitro kinase assays are conducted at low ATP 
concentrations which increases the apparent but not actual potency of the antagonists. It 
is possible that the absence of inhibitory activity of genistein on PDGF receptor 
phosphorylation in intact cells arises due to the relatively very high (millimolar) 
intracellular concentration of ATP [43, 44]. To evaluate the possibility that genistein is 
not inhibitory in intact VSMCs because it cannot compete with the high ATP 
concentration, we undertook the in vitro kinase assays at a wide range of ATP 
concentrations (10-200 µM). There was no effect of the ATP concentration (up to the 
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maximum level tested) on the activity of genistein to inhibit PDGF receptor kinase 
activity (Fig. 5, lower panel). 
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4 Discussion 
In this work we demonstrate that the prototypical receptor tyrosine kinase inhibitor 
genistein does not block PDGF stimulated phosphorylation of the autophosphorylation 
site nor of two other phosphorylation sites on the PDGFβ receptor in human VSMCs. 
This result provides the explanation for the observation that genistein does not block 
PDGF stimulated GAG elongation on proteoglycans secreted by these cells because we 
have reported that this response does involve PDGF receptor phosphorylation [13, 25]. 
Genistein does block proteoglycan core protein expression but this is due to an action 
elsewhere than in the PDGFβ receptor signaling cascade as has been demonstrated for the 
effect of genistein on VSMC proliferation in which the target is p27
kip1
 [22].  
It has been reported that PDGF stimulates proteoglycan core protein expression and 
elongation of GAG CS/DS chains on proteoglycans secreted by VSMCs but only core 
protein expression and not the GAG elongation effect is blocked by the isoflavone 
tyrosine kinase inhibitor genistein [18]. On the basis that genistein is a protein tyrosine 
kinase inhibitor, this data lead to the conclusion that the GAG elongation effect did not 
involve PDGF receptor phosphorylation [18]. We have recently reported that two PDGF 
receptor antagonists, imatinib and Ki11502, block PDGF receptor β phosphorylation and 
also block PDGF stimulated GAG elongation [13, 25]. On this background we 
investigated the effects of genistein on PDGF receptor phosphorylation and signaling and 
proteoglycan synthesis in human VSMCs. 
In the current paper we confirm that genistein does not block the GAG elongation 
effect of PDGF in VSMCs. We demonstrate that genistein does not block 
phosphorylation of the autophosphorylation site of the PDGF receptor β which is the 
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predominant receptor type regulating proteoglycan expression in these cells [25] nor does 
it block the phosphorylation of two other sites on the PDGF receptor. Taken with the data 
on the inhibitory effect of the PDGF receptor antagonists, imatinib and Ki11502, this 
strongly suggests that PDGF-stimulated GAG elongation is initiated at and mediated by 
the PDGF receptor and its phosphorylation and downstream signaling. As we could 
unequivocally demonstrate that genistein was a highly efficacious albeit low potency 
inhibitor of PDGF receptor kinase activity in a direct kinase assay (Fig. 5), we further 
investigated the possible reason for the absence of an inhibitory effect of genistein on 
PDGF receptor phosphorylation in intact cells. We examined the role of the ATP 
concentration on the basis that being a competitive inhibitor, a high concentration of ATP 
might greatly reduce the potency of genistein.  We demonstrated that the absence of an 
inhibitory effect on PDGF receptor phosphorylation was not due to competitive inhibition 
by the high level of ATP in intact cells.  
Genistein blocks PDGF-stimulated versican expression in monkey VSMCs and we 
demonstrated that it also blocks PDGF-stimulated versican expression in human VSMCs 
(Fig. 2.). That genistein demonstrates some cellular activity indicates that the drug is 
getting into the cells albeit that there could be concentration differentials but this is 
unlikely as the experiments are conducted over the relatively long period of 24 h. Noting 
the absence of an effect of genistein on PDGF receptor phosphorylation this indicates that 
this is not the point of action of genistein in blocking proteoglycan core protein 
expression. In studies of VSMC proliferation genistein inhibits proliferation due to an 
action targeted at the cell cycle, such as the level of p27
kip1
 rather than the receptor 
phosphorylation and immediate downstream signaling [22]. It is likely that the action of 
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genistein to block PDGF-stimulated versican expression also resides in cell cycle related 
pathways. This data indicates that there are distinct signaling pathways for proteoglycan 
core protein expression and GAG elongation as originally suggested by Schonherr and 
colleagues [18].  
Cell cycle progression is dependent upon a fall in the level of p27
kip1
 and although 
genistein inhibits VSMC proliferation by blocking the decrease in p27
kip1
 levels it 
remains unclear if the inhibitory action of genistein involves inhibition of protein tyrosine 
kinase activity at a site other than the PDGF receptor. Cells contain numerous tyrosine 
kinases which may be targets for genistein although whether or not any of these are 
upstream of the regulation of p27
kip1
 remains unknown. Mutation of the critical tyrosine 
in the autotransphosphorylation and activation site of the PDGF receptor β, Tyr857 in the 
PDGF receptor β to an amino acid (phenylalanine) which cannot be phosphorylated does 
not reduce the level overall phosphorylation of the receptor in porcine aortic endothelia 
cells [45]. This suggests that another kinase, as yet unidentified, participates in the 
phosphorylation of the PDGF receptor upon treatment of cells with PDGF. In this model 
it is conceivable that genistein, which inhibits PDGF receptor β kinase activity in vitro 
does not inhibit PDGF receptor β phosphorylation in intact cells because it does not 
inhibit the activity of this kinase [45]. 
 
5 Conclusions 
In this work we have demonstrated that genistein in intact VSMCs does not block 
autophosphorylation and activation of the receptor for PDGF. Taken with the data for 
imatinib and Ki11502 this demonstrates that PDGF-stimulated GAG elongation is 
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initiated at and mediated by the PDGF receptor and its phosphorylation. Insofar as 
inhibition of VSMC proliferation is concerned the inhibitory action of genistein resides in 
cell cycle events rather than inhibition of the PDGF receptor signaling pathway. 
Accordingly, the inhibition of core protein expression (biglycan and versican) may also 
be occurring elsewhere than the primary PDGF receptor associated signaling pathway. 
The data extends our understanding of the growth factor and hormone signaling pathways 
that regulate proteoglycan synthesis in vascular smooth muscle and advances research 
into the identification and development of a proteoglycan synthesis inhibitor which has 
the potential to act in concert with a statin drug for the prevention of disease dependent 
upon lipid deposition in tissues such as atherosclerosis. 
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Figure 1.  Role of PDGF receptor in PDGF-stimulated proteoglycan synthesis in 
human VSMCs. 
VSMCs were pre-treated for 30 min with Imatinib (Imat), Genistein (Gen) or Daidzein 
(Daid) and then stimulated with PDGF (50 ng/ml) for 24 h in the presence of [
35
S]-
sulfate. (Upper panel). SDS-PAGE analysis of [
35
S]-sulfate incorporated samples (Lower 
panel). Histogram values are expressed as percentage of untreated control value *P <0.05 
and ** P<0.01 vs agonist for 3 independent experiments in triplicate. 
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Figure 2. Role of PDGF receptor in PDGF-stimulated proteoglycan core protein 
synthesis in human VSMCs. 
VSMCs were pre-treated for 30 min with Ki11502 (Ki), Imatinib (Imat), Genistein (Gen) 
or Daidzein (Daid) and then stimulated with PDGF (50 ng/ml) for 24 h in the presence of 
[
35
S]-Met/Cys 24 h. (Upper panel).  Human VSMCs were treated with PDGF (50 ng/ml) 
and the expression of versican (lower panel) determined by RT-PCR as described in 
Materials and Methods.  
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Figure 3. Pharmacology of PDGF induced tyrosine phosphorylation of multiple sites 
on the PDGFβ receptor. Western blots of human VSMCs untreated or treated with 
PDGF-BB (50 ng/ml) for 20 min in the presence of Ki11502 (Ki), Genistein (Gen) or 
Imatinib (Imat). PDGFRβ was probed with anti-phosphoTyr857, anti-phosphoTyr751, or 
anti-phosphoTyr
1021
 antibodies as indicated and analysis of whole cell protein tyrosine 
phosphorylation (right hand panel) probed with anti-phosphotyrosine 4G10 antibody. 
Arrowheads identify PDGF-induced phosphotyrosine proteins that are affected by 
genistein pre-treatment. Membranes were reprobed for smooth muscle α-actin or 
GAPDH. 
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Figure 4. Egr-1 mRNA and protein levels in SMCs pre-treated with inhibitors Genistein 
(Gen), Imatinib (Imat), Daidzein (Daid) or solvent (Dimethylsulfoxide, DMSO) for 1 h 
then exposed to PDGF-BB for 30 min.  Egr-1 mRNA experiments were carried out with 
HSMCs. Egr-1 Western blotting was performed with total extracts from WKY12-22 
cells.  
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Figure 5.  Characterisation of PDGF inhibitors against PDGF receptor kinase 
activity in a cell free system.  
The inhibitory activities of putative PDGF receptor inhibitors against PDGFβ receptor 
tyrosine kinase activity using the Alphascreen™ P-Tyr-100 (phosphotyrosine) assay kit 
as describe din Materials and Methods (upper panel). The effect of varying the ATP 
concentration in the assay on the inhibitory effect of genistein is shown below (lower 
panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page 1 
 
 
 
Table 1.Pharmacological parameters for the inhibition of PDGF receptor kinase 
activity by putative inhibitors. The table shows the mathematical analyses of the data in 
Fig. upper panel based on a logistical fit of the data generated as described in Materials 
and Methods 
 
Parameter Ki11502 Imatinib Genistein Daidzein 
IC50 (nM) 71.2 111.6 9250 >10,000 
Lower fit (%) 84.3 73.7 106.3 19.8 
Upper fit (%) 36.9 4.1 - 3.4 1.4 
R
2 
(%) 96.3 98.9 98.4 34.6 
n 10 10 7 7 
 
 
  
Highlights 
 
- Genistein does not block PDGF mediated elongation of glycosaminoglycan chains on 
proteoglycans  
- Imatinib and Ki11502 block PDGF stimulated PDGF receptor phosphorylation  
- Genistein does not block PDGF stimulated phosphorylation of the PDGF receptor 
- Genistein blocks PDGF receptor kinase activity in vitro  
- Absence of inhibitory action of genistein is not due to high ATP concentration 
